Pradhananga, S., Salvail, W., Campeau, E., Srinivasan, D., Vidal, M., Truex, P., Odink, D., Das, S., Sehnert, A. (2025). Abstract 4369238: THRV-1268, a potent and selective serum and glucocorticoid regulated kinase (SGK1) inhibitor, improves adverse cardiac remodeling better than Jardiance® (empagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor in heart failure. Circulation. https://doi.org/10.1161/circ.152.suppl_3.4369238